A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives
- 15 April 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (4) , 711-720
- https://doi.org/10.1016/0277-5379(89)90208-3
Abstract
No abstract availableThis publication has 45 references indexed in Scilit:
- Meta-Analyses of Randomized Controlled TrialsNew England Journal of Medicine, 1987
- Tumor ploidy as a major prognostic factor in advanced ovarian cancerCancer, 1987
- Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.Journal of Clinical Oncology, 1986
- Prognostic factors in advanced ovarian carcinoma.Journal of Clinical Oncology, 1986
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation)American Journal of Obstetrics and Gynecology, 1983
- A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinomaCancer, 1983
- Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)Cancer, 1981
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978
- Primary, Secondary, and Meta-Analysis of ResearchEducational Researcher, 1976